There is an unmet need for effective treatment strategies to reduce morbidity and mortality in
patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Abstract Ethnopharmacological relevance Tsantan Sumtang, which consists of
Choerospondias axillaris (Roxb.) Burtt et Hill, Myristica fragrans Houtt and Santalum album …

Right ventricular failure predicts adverse outcome in patients with pulmonary hypertension
(PH), and in subjects with left ventricular heart failure and is associated with interstitial …

Right ventricular (RV) failure (RVF) has garnered significant attention in recent years
because of its negative impact on clinical outcomes in patients with pulmonary hypertension …

Reactive oxygen species (ROS) exert signaling character (redox signaling), or damaging
character (oxidative stress) on cardiac tissue depending on their concentration and/or …

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition
is still characterized by an extremely poor prognosis. In this review, we discuss the use of …

Pulmonary arterial hypertension (PAH) is a rare disease of unknown etiology that
progresses to right ventricular failure. It has a complex pathophysiology, which involves an …

Sympathetic overactivation plays an important role in promoting a variety of
pathophysiological processes in cardiovascular diseases (CVDs), including ventricular …

The most common cause of heart failure in the United States is ischemic left heart disease;
accordingly, a vast amount of work has been done to elucidate the molecular mechanisms …